11:@0.890196:0.957873:0.905593:0.957873:0.905593:0.938882:0.890196:0.938882:0.006807:0.008591
1:@0.941813:0.186378:0.963291:0.186378:0.963291:0.138900:0.941813:0.138900:0.021478
introduction:@0.794874:0.064721:0.882352:0.064721:0.882352:0.047603:0.794874:0.047603:0.003511:0.008759:0.006387:0.008311:0.008442:0.008423:0.008367:0.008178:0.006387:0.003511:0.008442:0.008759
used to explore targeted treatments. Drug screening in breast cancer organoids with :@0.147059:0.121273:0.886464:0.121273:0.886464:0.100900:0.147059:0.100900:0.011413:0.007875:0.009108:0.011391:0.007177:0.006209:0.011048:0.007179:0.009108:0.010089:0.011162:0.005182:0.010843:0.007442:0.009039:0.007177:0.006551:0.009087:0.007624:0.009653:0.009131:0.006211:0.009106:0.011391:0.007179:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.007670:0.004497:0.007177:0.016024:0.007967:0.011413:0.009861:0.007179:0.007875:0.008994:0.007442:0.009108:0.009039:0.011756:0.005615:0.011459:0.009861:0.007177:0.005615:0.011756:0.007179:0.010820:0.007442:0.009288:0.009291:0.007512:0.006437:0.007179:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.007179:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.007670:0.007179:0.014723:0.005271:0.006620:0.011459:0.004109
several drugs targeting the HER signalling pathway revealed that specific organoid :@0.147059:0.141852:0.886503:0.141852:0.886503:0.121479:0.147059:0.121479:0.007875:0.009336:0.009633:0.009039:0.007898:0.009405:0.005250:0.008720:0.011391:0.007964:0.011413:0.009724:0.007670:0.008720:0.006551:0.009085:0.007624:0.009656:0.009131:0.006437:0.005615:0.011459:0.009861:0.008720:0.006620:0.011299:0.009039:0.008720:0.016846:0.012098:0.013376:0.008720:0.007601:0.005615:0.009861:0.011687:0.009405:0.005387:0.005250:0.005615:0.011459:0.009861:0.008720:0.011365:0.008811:0.006620:0.011071:0.014723:0.008925:0.009724:0.008720:0.007442:0.009334:0.009635:0.009288:0.009405:0.005182:0.009108:0.011391:0.008720:0.006620:0.011391:0.008811:0.006437:0.008720:0.007510:0.011505:0.009108:0.008994:0.005615:0.005684:0.005615:0.008994:0.008720:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.004109
responses depend on HER2 expression status . Separately, prostate cancer organoids :@0.147059:0.162431:0.886424:0.162431:0.886424:0.142058:0.147059:0.142058:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.007670:0.006118:0.011322:0.009131:0.011505:0.009039:0.011596:0.011391:0.006118:0.010843:0.011756:0.006118:0.016846:0.012098:0.013376:0.010432:0.006118:0.009108:0.010089:0.011071:0.007442:0.009039:0.007533:0.007601:0.005547:0.010843:0.011756:0.006118:0.007510:0.006551:0.008811:0.006163:0.011413:0.007670:0.018290:0.004497:0.006118:0.010592:0.009131:0.011368:0.009085:0.007898:0.008811:0.006209:0.008948:0.005182:0.007989:0.004497:0.006118:0.011071:0.007442:0.010957:0.007510:0.006551:0.008811:0.006209:0.009039:0.006118:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.006118:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.007670:0.004109
135:@0.537716:0.154815:0.555962:0.154815:0.555962:0.142937:0.537716:0.142937:0.006082:0.006082:0.006082
with androgen receptor (AR) amplification showed higher sensitivity to enzalutamide, :@0.147059:0.183009:0.886462:0.183009:0.886462:0.162636:0.147059:0.162636:0.014723:0.005273:0.006620:0.011459:0.005670:0.009085:0.011596:0.011391:0.007442:0.011048:0.009656:0.009039:0.011756:0.005672:0.007442:0.009108:0.008994:0.009131:0.011048:0.006209:0.010843:0.007807:0.005670:0.006939:0.014929:0.013376:0.006939:0.005670:0.009085:0.017282:0.011162:0.005250:0.005615:0.005684:0.005613:0.009108:0.008811:0.006437:0.005547:0.010843:0.011756:0.005672:0.007556:0.011299:0.010866:0.014518:0.009108:0.011391:0.005670:0.011459:0.005615:0.009930:0.011299:0.009039:0.007807:0.005670:0.007875:0.009039:0.011619:0.007601:0.005273:0.006437:0.005547:0.009838:0.005273:0.006437:0.009724:0.005672:0.006209:0.011048:0.005670:0.009039:0.011756:0.008834:0.009405:0.004908:0.011071:0.006551:0.009085:0.017645:0.005547:0.011322:0.008743:0.004497:0.004109
an AR inhibitor, than the rest of the organoids . Overall, despite several limitations and :@0.147059:0.203588:0.886458:0.203588:0.886458:0.183215:0.147059:0.183215:0.009085:0.011756:0.003949:0.014929:0.013376:0.003949:0.005615:0.011870:0.011459:0.005547:0.010820:0.005273:0.006209:0.010843:0.006255:0.004497:0.003949:0.006620:0.011391:0.009087:0.011756:0.003949:0.006620:0.011299:0.009039:0.003949:0.007442:0.009039:0.007510:0.006437:0.003949:0.010845:0.006209:0.003949:0.006620:0.011299:0.009039:0.003949:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.007670:0.018251:0.004497:0.003949:0.016892:0.009633:0.009039:0.007898:0.009405:0.005387:0.004976:0.004497:0.003949:0.011322:0.009039:0.007510:0.011071:0.005273:0.006209:0.009039:0.003949:0.007875:0.009336:0.009633:0.009039:0.007898:0.009405:0.005250:0.003949:0.005250:0.005615:0.017645:0.005273:0.006551:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.003949:0.009085:0.011596:0.011391:0.004109
127:@0.530902:0.195972:0.549147:0.195972:0.549147:0.184095:0.530902:0.184095:0.006082:0.006082:0.006082
awaiting larger cohort clinical characterizations, organoids have emerged as exciting and :@0.147059:0.224167:0.886489:0.224167:0.886489:0.203794:0.147059:0.203794:0.008925:0.014723:0.009085:0.005273:0.006437:0.005615:0.011459:0.009861:0.003721:0.005433:0.009085:0.007624:0.009656:0.009039:0.007807:0.003721:0.008994:0.010934:0.011299:0.010843:0.007967:0.006437:0.003721:0.008765:0.005250:0.005615:0.011756:0.005547:0.009106:0.009405:0.005250:0.003721:0.008765:0.011391:0.009085:0.007898:0.009291:0.009108:0.006209:0.009039:0.007807:0.005615:0.008834:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004497:0.003721:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.007670:0.003721:0.011391:0.008925:0.009633:0.009039:0.003721:0.009039:0.017485:0.009039:0.007624:0.009656:0.009108:0.011391:0.003721:0.009291:0.007670:0.003721:0.009108:0.009884:0.008994:0.005273:0.006437:0.005615:0.011461:0.009861:0.003721:0.009087:0.011596:0.011391:0.004109
promising :@0.147059:0.244745:0.238320:0.244745:0.238320:0.224373:0.147059:0.224373:0.011071:0.007442:0.010843:0.017645:0.005615:0.007601:0.005615:0.011459:0.009861:0.004109
in vitro:@0.238944:0.244745:0.297769:0.244745:0.297769:0.224162:0.238944:0.224162:0.005090:0.011299:0.004839:0.009291:0.005205:0.005866:0.007305:0.009930
 models to bridge the gap between bench cancer research and clinical :@0.297767:0.244745:0.886376:0.244745:0.886376:0.224373:0.297767:0.224373:0.004725:0.017488:0.011276:0.011322:0.008948:0.005250:0.007670:0.004725:0.006209:0.011048:0.004725:0.010820:0.007807:0.005547:0.011391:0.009656:0.009039:0.004725:0.006620:0.011299:0.009039:0.004725:0.009861:0.008811:0.011276:0.004725:0.011251:0.009131:0.006437:0.014518:0.009108:0.009039:0.011756:0.004725:0.011251:0.009039:0.011598:0.008765:0.011459:0.004725:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.004725:0.007442:0.009039:0.007875:0.009288:0.009085:0.007442:0.008765:0.011459:0.004725:0.009085:0.011596:0.011391:0.004725:0.008765:0.005250:0.005615:0.011756:0.005549:0.009106:0.009405:0.005250:0.004109
care. :@0.147059:0.265324:0.190042:0.265324:0.190042:0.244951:0.147059:0.244951:0.009108:0.009085:0.007442:0.008743:0.004497:0.004109
Structural variation in cancer:@0.147059:0.330043:0.472961:0.330043:0.472961:0.301932:0.147059:0.301932:0.012028:0.010343:0.013015:0.013015:0.012725:0.010343:0.013015:0.013103:0.012318:0.009991:0.004358:0.010836:0.012318:0.013103:0.006217:0.011040:0.010343:0.006217:0.013132:0.013626:0.004648:0.006217:0.013626:0.004648:0.012722:0.012318:0.013626:0.012841:0.011069:0.013103
One of the aforementioned hallmarks of cancer, particularly relevant in OC, is :@0.147059:0.374685:0.886553:0.374685:0.886553:0.354312:0.147059:0.354312:0.016298:0.011596:0.009039:0.011573:0.010843:0.006209:0.011573:0.006620:0.011299:0.009039:0.011573:0.009085:0.006026:0.010843:0.007442:0.009039:0.017485:0.009039:0.011391:0.006437:0.005547:0.010843:0.011598:0.009106:0.011391:0.011573:0.011391:0.009405:0.005387:0.005250:0.017577:0.009085:0.007601:0.010523:0.007670:0.011573:0.010843:0.006209:0.011573:0.009108:0.009085:0.011596:0.008994:0.009039:0.006255:0.004497:0.011573:0.011368:0.009085:0.007964:0.006437:0.005547:0.009108:0.011550:0.005433:0.009085:0.007601:0.005182:0.009724:0.011573:0.007442:0.008948:0.005182:0.009336:0.009838:0.009085:0.011391:0.006437:0.011573:0.005615:0.011756:0.011573:0.016778:0.014678:0.004497:0.011573:0.005615:0.007670:0.004109
chromosomal instability . Directly related to genomic instability are SVs and in particular :@0.147059:0.395264:0.886368:0.395264:0.886368:0.374891:0.147059:0.374891:0.008765:0.011459:0.007442:0.010843:0.017485:0.010957:0.007875:0.010843:0.017577:0.009405:0.005250:0.002853:0.005615:0.011619:0.007510:0.006551:0.009108:0.010820:0.005752:0.005250:0.005273:0.006437:0.009724:0.006090:0.004497:0.002853:0.016024:0.005615:0.007442:0.009108:0.009108:0.006620:0.005182:0.009724:0.002853:0.007442:0.008948:0.005433:0.008811:0.006209:0.009108:0.011391:0.002853:0.006209:0.011048:0.002853:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.002853:0.005615:0.011619:0.007510:0.006551:0.009108:0.010820:0.005752:0.005250:0.005273:0.006437:0.009724:0.002853:0.009085:0.007442:0.009039:0.002853:0.010112:0.015089:0.007670:0.002853:0.009085:0.011598:0.011391:0.002853:0.005615:0.011756:0.002853:0.011368:0.009085:0.007964:0.006437:0.005547:0.009108:0.011550:0.005433:0.009085:0.007807:0.004109
9:@0.351481:0.387648:0.357563:0.387648:0.357563:0.375770:0.351481:0.375770:0.006082
somatic SVs. As previously discussed, SVs and copy number alterations (CNAs) have a :@0.147059:0.415843:0.886528:0.415843:0.886528:0.395470:0.147059:0.395470:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.004953:0.010112:0.015089:0.007670:0.004497:0.004953:0.014586:0.007670:0.004953:0.011071:0.007442:0.009336:0.009838:0.005547:0.010820:0.011413:0.007556:0.005182:0.009724:0.004953:0.011391:0.005615:0.007873:0.009108:0.011413:0.007533:0.007875:0.009108:0.011117:0.004497:0.004953:0.010112:0.015089:0.007670:0.004953:0.009085:0.011596:0.011391:0.004953:0.008994:0.010818:0.011094:0.009724:0.004953:0.011391:0.011413:0.017394:0.011254:0.009039:0.007807:0.004953:0.009405:0.004908:0.006209:0.009039:0.007898:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004953:0.006939:0.014678:0.015408:0.014586:0.007670:0.006939:0.004953:0.011391:0.008925:0.009633:0.009039:0.004953:0.009291:0.004109
critical role in tumorigenesis  and most tumors bear a considerable amount of somatic :@0.147059:0.436421:0.886415:0.436421:0.886415:0.416048:0.147059:0.416048:0.008994:0.007807:0.005273:0.006437:0.005547:0.009108:0.009405:0.005250:0.004200:0.007442:0.010934:0.005182:0.009039:0.004200:0.005615:0.011756:0.004200:0.006163:0.011413:0.017485:0.010843:0.007807:0.005615:0.009656:0.009039:0.011596:0.009039:0.007601:0.005615:0.007670:0.018259:0.004200:0.009085:0.011596:0.011391:0.004200:0.017485:0.010957:0.007510:0.006437:0.004200:0.006163:0.011413:0.017485:0.010843:0.007624:0.007670:0.004200:0.011254:0.009291:0.009085:0.007807:0.004200:0.009291:0.004200:0.008994:0.010843:0.011621:0.007601:0.005547:0.011322:0.009039:0.007896:0.009108:0.010911:0.005182:0.009039:0.004200:0.009085:0.017485:0.010820:0.011413:0.011391:0.006437:0.004200:0.010843:0.006209:0.004200:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.004109
141:@0.387005:0.428805:0.405250:0.428805:0.405250:0.416928:0.387005:0.416928:0.006082:0.006082:0.006082
SVs. Furthermore, it has been shown that some cancers are primarily driven by somatic :@0.147059:0.457000:0.886459:0.457000:0.886459:0.436627:0.147059:0.436627:0.010112:0.015089:0.007670:0.004497:0.004460:0.010729:0.011413:0.007967:0.006620:0.011299:0.009039:0.007807:0.017485:0.010843:0.007442:0.008743:0.004497:0.004463:0.005273:0.006437:0.004460:0.011391:0.009291:0.007670:0.004463:0.011254:0.009106:0.009039:0.011756:0.004463:0.007556:0.011299:0.010866:0.014723:0.011756:0.004463:0.006620:0.011391:0.008811:0.006437:0.004460:0.007875:0.010843:0.017485:0.009039:0.004463:0.009108:0.009085:0.011596:0.008994:0.009039:0.007624:0.007670:0.004460:0.009085:0.007442:0.009039:0.004463:0.011071:0.007807:0.005615:0.017577:0.009085:0.007807:0.005752:0.005182:0.009724:0.004460:0.011391:0.007807:0.005547:0.009633:0.009039:0.011756:0.004463:0.010843:0.009724:0.004460:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.004109
SVs, e.g. high grade serous ovarian , esophageal , neuroblastoma , small-cell lung :@0.147059:0.477579:0.886451:0.477579:0.886451:0.457206:0.147059:0.457206:0.010112:0.015089:0.007670:0.004497:0.007145:0.008743:0.004497:0.009679:0.004497:0.007145:0.011459:0.005615:0.009927:0.011459:0.007145:0.009861:0.007898:0.009291:0.011322:0.009039:0.007145:0.007875:0.009039:0.007442:0.010820:0.011413:0.007670:0.007145:0.010866:0.009838:0.009085:0.007807:0.005798:0.009085:0.011756:0.012185:0.004497:0.007145:0.009039:0.007875:0.010820:0.011162:0.011391:0.009199:0.009656:0.009291:0.009402:0.005250:0.018250:0.004497:0.007145:0.011596:0.009131:0.011413:0.007442:0.010957:0.010911:0.005433:0.009291:0.007510:0.006209:0.010843:0.017577:0.009291:0.018249:0.004497:0.007145:0.007601:0.017577:0.009405:0.005387:0.005250:0.007533:0.008994:0.008946:0.005387:0.005250:0.007145:0.004908:0.011413:0.011459:0.009861:0.004109
77:@0.451953:0.469963:0.464116:0.469963:0.464116:0.458085:0.451953:0.458085:0.006082:0.006082
142:@0.568848:0.469963:0.587094:0.469963:0.587094:0.458085:0.568848:0.458085:0.006082:0.006082:0.006082
143:@0.726341:0.469963:0.744586:0.469963:0.744586:0.458085:0.726341:0.458085:0.006082:0.006082:0.006082
cancer  and triple-negative breast cancer , with the majority of somatic SV events :@0.147059:0.498157:0.886454:0.498157:0.886454:0.477785:0.147059:0.477785:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.018245:0.007190:0.009085:0.011596:0.011391:0.007190:0.006437:0.007807:0.005273:0.011162:0.005182:0.009039:0.007533:0.011596:0.009039:0.009861:0.008811:0.006437:0.005547:0.009633:0.009039:0.007190:0.010820:0.007442:0.009291:0.009291:0.007510:0.006437:0.007190:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.018248:0.004497:0.007190:0.014723:0.005271:0.006620:0.011459:0.007190:0.006620:0.011299:0.009039:0.007190:0.017577:0.008811:0.005341:0.010843:0.007807:0.005273:0.006437:0.009724:0.007190:0.010843:0.006209:0.007190:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.007190:0.010112:0.015089:0.007190:0.009336:0.009633:0.009039:0.011391:0.006437:0.007670:0.004109
144:@0.202688:0.490541:0.220933:0.490541:0.220933:0.478664:0.202688:0.478664:0.006082:0.006082:0.006082
145:@0.510585:0.490541:0.528830:0.490541:0.528830:0.478664:0.510585:0.478664:0.006082:0.006082:0.006082
being non-recurrent even within cancer types .:@0.147059:0.518736:0.553697:0.518736:0.553697:0.498363:0.147059:0.498363:0.011254:0.009039:0.005615:0.011459:0.009861:0.004109:0.011596:0.010843:0.011756:0.007533:0.007442:0.009108:0.009106:0.011413:0.007807:0.007442:0.009039:0.011393:0.006437:0.004109:0.009334:0.009633:0.009039:0.011756:0.004109:0.014723:0.005273:0.006620:0.011459:0.005615:0.011756:0.004109:0.009106:0.009087:0.011596:0.008994:0.009039:0.007807:0.004109:0.006437:0.009724:0.011502:0.009039:0.007670:0.018245:0.004497
146:@0.530956:0.511120:0.549201:0.511120:0.549201:0.499243:0.530956:0.499243:0.006082:0.006082:0.006082
Apart from the simple deletion, inversion, translocation, duplication and insertion SV :@0.147059:0.559894:0.886507:0.559894:0.886507:0.539521:0.147059:0.539521:0.013993:0.011368:0.009085:0.007967:0.006437:0.005752:0.006414:0.007442:0.010843:0.017645:0.005752:0.006620:0.011299:0.009039:0.005752:0.007601:0.005615:0.017280:0.011162:0.005182:0.009039:0.005752:0.011322:0.008950:0.005182:0.009128:0.006437:0.005547:0.010843:0.011756:0.004497:0.005752:0.005615:0.011368:0.009633:0.009039:0.007624:0.007601:0.005547:0.010843:0.011756:0.004497:0.005752:0.006437:0.007898:0.009085:0.011619:0.007556:0.005182:0.011276:0.009108:0.008811:0.006437:0.005547:0.010843:0.011756:0.004497:0.005752:0.011048:0.011071:0.011162:0.005250:0.005547:0.009108:0.008811:0.006437:0.005547:0.010843:0.011756:0.005752:0.009085:0.011596:0.011391:0.005752:0.005615:0.011619:0.007873:0.009039:0.007967:0.006437:0.005547:0.010843:0.011756:0.005752:0.010112:0.015089:0.004109
events previously described, more complex SV phenomena with multiple clustered :@0.147059:0.580472:0.886441:0.580472:0.886441:0.560099:0.147059:0.560099:0.009336:0.009633:0.009039:0.011391:0.006437:0.007670:0.008720:0.011071:0.007442:0.009336:0.009838:0.005547:0.010820:0.011413:0.007556:0.005182:0.009724:0.008720:0.011322:0.009039:0.007875:0.008994:0.007807:0.005547:0.011254:0.009108:0.011117:0.004497:0.008720:0.017485:0.010843:0.007442:0.009039:0.008720:0.008994:0.010843:0.017280:0.011162:0.005182:0.009108:0.010089:0.008720:0.010112:0.015089:0.008720:0.011162:0.011299:0.009039:0.011596:0.010843:0.017485:0.009039:0.011687:0.009291:0.008720:0.014723:0.005273:0.006620:0.011459:0.008720:0.017280:0.011550:0.004908:0.006437:0.005273:0.011162:0.005182:0.009039:0.008720:0.008765:0.004908:0.011413:0.007510:0.006209:0.009039:0.007442:0.009108:0.011391:0.004109
genomic rearrangement are very common in cancer. Breakage-fusion-bridge (BFB) :@0.147059:0.601051:0.886393:0.601051:0.886393:0.580678:0.147059:0.580678:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.008834:0.007442:0.009291:0.009085:0.007807:0.007898:0.009085:0.011459:0.009656:0.009039:0.017485:0.009039:0.011391:0.006437:0.008834:0.009085:0.007442:0.009039:0.008834:0.009633:0.009039:0.008400:0.009724:0.008834:0.008994:0.010843:0.017645:0.017485:0.010843:0.011756:0.008834:0.005615:0.011756:0.008834:0.009108:0.009085:0.011596:0.008994:0.009039:0.006255:0.004497:0.008834:0.012486:0.007442:0.009288:0.009405:0.010614:0.009199:0.009656:0.009039:0.007533:0.006369:0.011413:0.007601:0.005547:0.010843:0.011756:0.007533:0.010820:0.007807:0.005547:0.011391:0.009656:0.009039:0.008834:0.006939:0.012463:0.011276:0.012646:0.006939:0.004109
events, which are the consequence of cycles of DNA breakage and sister-chromatid fusion :@0.147059:0.621630:0.886418:0.621630:0.886418:0.601257:0.147059:0.601257:0.009336:0.009633:0.009039:0.011391:0.006437:0.007670:0.004497:0.002808:0.014789:0.011459:0.005547:0.008765:0.011459:0.002808:0.009085:0.007442:0.009039:0.002808:0.006620:0.011299:0.009039:0.002808:0.008994:0.010843:0.011619:0.007875:0.009106:0.010706:0.011345:0.009039:0.011598:0.008994:0.009039:0.002808:0.010843:0.006209:0.002808:0.009382:0.009519:0.008765:0.005182:0.009039:0.007670:0.002808:0.010843:0.006209:0.002808:0.015773:0.015408:0.014929:0.002808:0.010820:0.007442:0.009291:0.009405:0.010612:0.009201:0.009656:0.009039:0.002808:0.009085:0.011598:0.011391:0.002808:0.007601:0.005615:0.007510:0.006209:0.009039:0.007236:0.007533:0.008765:0.011459:0.007442:0.010843:0.017577:0.008811:0.006437:0.005547:0.011391:0.002808:0.006369:0.011413:0.007601:0.005547:0.010843:0.011756:0.004109
that cause a dicentric chromosome that bridges during cell division, leading to further :@0.147059:0.642208:0.886505:0.642208:0.886505:0.621835:0.147059:0.621835:0.006620:0.011391:0.008811:0.006437:0.005478:0.009108:0.008811:0.011413:0.007875:0.009039:0.005478:0.009291:0.005478:0.011391:0.005547:0.008994:0.009039:0.011391:0.006437:0.007807:0.005547:0.008994:0.005478:0.008765:0.011459:0.007442:0.010843:0.017485:0.010957:0.007875:0.010843:0.017485:0.009039:0.005478:0.006620:0.011391:0.008811:0.006437:0.005478:0.010820:0.007807:0.005547:0.011391:0.009656:0.009039:0.007670:0.005478:0.011048:0.011413:0.007807:0.005615:0.011459:0.009861:0.005478:0.008994:0.008948:0.005385:0.005250:0.005478:0.011391:0.005547:0.009838:0.005615:0.007601:0.005547:0.010843:0.011756:0.004497:0.005478:0.005182:0.009291:0.009291:0.011391:0.005615:0.011459:0.009861:0.005478:0.006209:0.011048:0.005478:0.006366:0.011413:0.007967:0.006620:0.011299:0.009039:0.007807:0.004109
breakages. BFB events show oscillating copy number changes surrounded by fold-back :@0.147059:0.662787:0.886395:0.662787:0.886395:0.642414:0.147059:0.642414:0.010820:0.007442:0.009291:0.009405:0.010614:0.009199:0.009656:0.009039:0.007670:0.004497:0.004953:0.012463:0.011276:0.012646:0.004953:0.009336:0.009633:0.009039:0.011391:0.006437:0.007670:0.004953:0.007556:0.011302:0.010863:0.014723:0.004953:0.010957:0.007875:0.008994:0.005752:0.005387:0.005433:0.008811:0.006437:0.005615:0.011459:0.009861:0.004953:0.008994:0.010820:0.011094:0.009724:0.004953:0.011391:0.011413:0.017394:0.011254:0.009039:0.007807:0.004953:0.008765:0.011391:0.009085:0.011459:0.009656:0.009039:0.007670:0.004953:0.007510:0.011413:0.007807:0.007442:0.010820:0.011413:0.011596:0.011322:0.009108:0.011391:0.004953:0.010843:0.009724:0.004953:0.006026:0.010934:0.005182:0.011391:0.007533:0.011114:0.009291:0.008768:0.010523:0.004109
inversions:@0.147059:0.683366:0.233618:0.683366:0.233618:0.662993:0.147059:0.662993:0.005615:0.011368:0.009633:0.009039:0.007624:0.007601:0.005547:0.010843:0.011619:0.007670
147–150:@0.233618:0.675750:0.276989:0.675750:0.276989:0.663872:0.233618:0.663872:0.006082:0.006082:0.006082:0.006880:0.006082:0.006082:0.006082
. Chromoplexy is a series of chained rearrangements involving several :@0.276987:0.683366:0.886483:0.683366:0.886483:0.662993:0.276987:0.662993:0.004497:0.006506:0.014746:0.011459:0.007442:0.010843:0.017485:0.010820:0.011162:0.005182:0.009108:0.010089:0.009724:0.006506:0.005615:0.007670:0.006506:0.009291:0.006506:0.007873:0.009039:0.007807:0.005547:0.009039:0.007670:0.006506:0.010843:0.006209:0.006506:0.008765:0.011391:0.009085:0.005615:0.011596:0.009108:0.011391:0.006506:0.007442:0.009291:0.009085:0.007807:0.007898:0.009085:0.011459:0.009656:0.009039:0.017485:0.009039:0.011391:0.006437:0.007670:0.006506:0.005615:0.011368:0.009633:0.010934:0.005182:0.009838:0.005615:0.011459:0.009861:0.006506:0.007875:0.009336:0.009633:0.009039:0.007898:0.009405:0.005250:0.004109
chromosomes resulting from simultaneous double stranded breaks that are erroneously :@0.147059:0.703944:0.886487:0.703944:0.886487:0.683572:0.147059:0.683572:0.008765:0.011459:0.007442:0.010843:0.017485:0.010957:0.007875:0.010843:0.017485:0.009039:0.007670:0.004291:0.007442:0.009039:0.007510:0.011550:0.004908:0.006437:0.005615:0.011459:0.009861:0.004291:0.006412:0.007442:0.010845:0.017645:0.004291:0.007601:0.005615:0.017280:0.011550:0.004908:0.006551:0.009085:0.011596:0.009108:0.010820:0.011413:0.007670:0.004291:0.011322:0.010820:0.011345:0.010911:0.005182:0.009039:0.004291:0.007510:0.006437:0.007898:0.009085:0.011596:0.011322:0.009108:0.011391:0.004291:0.010820:0.007442:0.009291:0.009405:0.010523:0.007670:0.004291:0.006620:0.011391:0.008811:0.006437:0.004291:0.009085:0.007442:0.009039:0.004291:0.009039:0.007807:0.007442:0.010843:0.011596:0.009108:0.010820:0.011413:0.007556:0.005182:0.009724:0.004109
repaired:@0.147059:0.724523:0.217639:0.724523:0.217639:0.704150:0.147059:0.704150:0.007442:0.009131:0.011368:0.009085:0.005615:0.007442:0.009108:0.011391
150,151:@0.217638:0.716907:0.256751:0.716907:0.256751:0.705030:0.217638:0.705030:0.006082:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082
. Chromothripsis involves a single chromosome shattering which creates up :@0.256749:0.724523:0.886497:0.724523:0.886497:0.704150:0.256749:0.704150:0.004497:0.003333:0.014746:0.011459:0.007442:0.010843:0.017485:0.010820:0.006620:0.011459:0.007807:0.005273:0.011185:0.007601:0.005615:0.007670:0.003333:0.005615:0.011368:0.009633:0.010934:0.005182:0.009633:0.009039:0.007670:0.003333:0.009291:0.003333:0.007601:0.005615:0.011459:0.009930:0.005182:0.009039:0.003333:0.008765:0.011459:0.007442:0.010843:0.017485:0.010957:0.007875:0.010843:0.017485:0.009039:0.003333:0.007556:0.011391:0.008813:0.006161:0.006211:0.009039:0.007807:0.005615:0.011459:0.009861:0.003333:0.014792:0.011459:0.005547:0.008765:0.011459:0.003333:0.008994:0.007442:0.009291:0.008811:0.006209:0.009039:0.007670:0.003333:0.011071:0.011276:0.004109
to hundreds of rearrangements in a single event. Chromothripsis is localized to a single :@0.147059:0.745102:0.886462:0.745102:0.886462:0.724729:0.147059:0.724729:0.006209:0.011048:0.004725:0.011094:0.011413:0.011596:0.011391:0.007442:0.009108:0.011391:0.007670:0.004725:0.010843:0.006209:0.004725:0.007442:0.009291:0.009085:0.007807:0.007898:0.009085:0.011459:0.009656:0.009039:0.017485:0.009039:0.011391:0.006437:0.007670:0.004725:0.005615:0.011756:0.004725:0.009291:0.004725:0.007601:0.005615:0.011459:0.009930:0.005182:0.009039:0.004725:0.009336:0.009633:0.009039:0.011391:0.006437:0.004497:0.004725:0.014746:0.011459:0.007442:0.010843:0.017485:0.010820:0.006620:0.011459:0.007807:0.005271:0.011185:0.007601:0.005615:0.007670:0.004725:0.005615:0.007670:0.004725:0.005182:0.011276:0.009108:0.009405:0.005250:0.005615:0.008834:0.009108:0.011391:0.004725:0.006209:0.011048:0.004725:0.009291:0.004725:0.007601:0.005615:0.011459:0.009930:0.005182:0.009039:0.004109
or a few chromosomes:@0.147059:0.765681:0.345421:0.765681:0.345421:0.745308:0.147059:0.745308:0.010843:0.007807:0.006825:0.009291:0.006825:0.006026:0.009334:0.014723:0.006825:0.008765:0.011459:0.007442:0.010843:0.017485:0.010957:0.007875:0.010843:0.017485:0.009039:0.007670
152–155:@0.345443:0.758065:0.388813:0.758065:0.388813:0.746187:0.345443:0.746187:0.006082:0.006082:0.006082:0.006880:0.006082:0.006082:0.006082
, and recent estimates show that up to 40% of all tumors :@0.388812:0.765681:0.886390:0.765681:0.886390:0.745308:0.388812:0.745308:0.004497:0.006825:0.009085:0.011596:0.011391:0.006825:0.007442:0.009108:0.008994:0.009039:0.011391:0.006437:0.006825:0.009039:0.007510:0.006437:0.005615:0.017577:0.008811:0.006209:0.009039:0.007670:0.006825:0.007556:0.011302:0.010863:0.014723:0.006825:0.006620:0.011391:0.008811:0.006437:0.006825:0.011071:0.011276:0.006825:0.006209:0.011048:0.006825:0.010432:0.010432:0.015043:0.006825:0.010843:0.006209:0.006825:0.009405:0.005387:0.005250:0.006825:0.006163:0.011413:0.017485:0.010843:0.007624:0.007670:0.004109
display chromothripsis events . :@0.147059:0.786259:0.425436:0.786259:0.425436:0.765886:0.147059:0.765886:0.011391:0.005615:0.007510:0.011162:0.005433:0.008925:0.009724:0.004109:0.008765:0.011459:0.007442:0.010843:0.017485:0.010820:0.006620:0.011459:0.007807:0.005273:0.011185:0.007601:0.005615:0.007670:0.004109:0.009334:0.009633:0.009039:0.011391:0.006437:0.007670:0.018245:0.004497:0.004109
156:@0.398586:0.778643:0.416831:0.778643:0.416831:0.766766:0.398586:0.766766:0.006082:0.006082:0.006082
There are diverse mechanisms through which somatic SVs can drive cancer : oncogene :@0.147059:0.827417:0.886466:0.827417:0.886466:0.807044:0.147059:0.807044:0.011470:0.011311:0.009039:0.007442:0.009039:0.003789:0.009085:0.007442:0.009039:0.003789:0.011391:0.005547:0.009633:0.009039:0.007624:0.007875:0.009039:0.003789:0.017485:0.009108:0.008765:0.011391:0.009085:0.011756:0.005615:0.007601:0.017508:0.007670:0.003789:0.006620:0.011459:0.007442:0.010820:0.011413:0.009930:0.011459:0.003789:0.014792:0.011459:0.005545:0.008765:0.011459:0.003789:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.003789:0.010112:0.015089:0.007670:0.003789:0.009108:0.009085:0.011756:0.003789:0.011391:0.007807:0.005547:0.009633:0.009039:0.003789:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.018197:0.004497:0.003789:0.010843:0.011596:0.008994:0.011048:0.009656:0.009039:0.011596:0.009039:0.004109
146:@0.774015:0.819801:0.792260:0.819801:0.792260:0.807923:0.774015:0.807923:0.006082:0.006082:0.006082
amplification via copy number alterations ; oncogenic gene fusions through deletions, :@0.147059:0.847995:0.886427:0.847995:0.886427:0.827622:0.147059:0.827622:0.009085:0.017280:0.011162:0.005250:0.005615:0.005684:0.005615:0.009108:0.008811:0.006437:0.005547:0.010843:0.011756:0.004428:0.009838:0.005798:0.009291:0.004428:0.008994:0.010818:0.011094:0.009724:0.004428:0.011391:0.011413:0.017396:0.011251:0.009039:0.007807:0.004428:0.009405:0.004908:0.006209:0.009039:0.007898:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.018273:0.004497:0.004428:0.010843:0.011596:0.008994:0.011048:0.009656:0.009039:0.011756:0.005547:0.008994:0.004428:0.009656:0.009039:0.011596:0.009039:0.004428:0.006369:0.011413:0.007601:0.005547:0.010843:0.011619:0.007670:0.004428:0.006620:0.011459:0.007442:0.010820:0.011413:0.009930:0.011459:0.004428:0.011322:0.008948:0.005182:0.009128:0.006437:0.005547:0.010845:0.011619:0.007670:0.004497:0.004109
157:@0.499233:0.840379:0.517479:0.840379:0.517479:0.828502:0.499233:0.828502:0.006082:0.006082:0.006082
translocations or inversions ; tumor-suppressor inactivation through deletion or gene :@0.147059:0.868574:0.886415:0.868574:0.886415:0.848201:0.147059:0.848201:0.006437:0.007898:0.009085:0.011619:0.007556:0.005182:0.011276:0.009108:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004885:0.010843:0.007807:0.004885:0.005615:0.011368:0.009633:0.009039:0.007624:0.007601:0.005547:0.010843:0.011619:0.007670:0.018260:0.004497:0.004885:0.006163:0.011413:0.017485:0.010843:0.007236:0.007533:0.007510:0.011071:0.011048:0.011071:0.007442:0.009039:0.007533:0.007875:0.010843:0.007807:0.004885:0.005615:0.011687:0.009291:0.009108:0.006437:0.005545:0.009838:0.008811:0.006437:0.005547:0.010843:0.011756:0.004885:0.006620:0.011459:0.007442:0.010820:0.011413:0.009930:0.011459:0.004885:0.011322:0.008948:0.005182:0.009131:0.006437:0.005547:0.010843:0.011756:0.004885:0.010843:0.007807:0.004885:0.009656:0.009039:0.011596:0.009039:0.004109
158:@0.381140:0.860958:0.399385:0.860958:0.399385:0.849081:0.381140:0.849081:0.006082:0.006082:0.006082
disruption, often coupled to inactivating mutations in the other allele, common for TP53 :@0.147059:0.889153:0.886510:0.889153:0.886510:0.868780:0.147059:0.868780:0.011391:0.005615:0.007601:0.007967:0.011071:0.011048:0.006437:0.005547:0.010843:0.011756:0.004497:0.003447:0.010843:0.006197:0.005969:0.009039:0.011756:0.003447:0.008994:0.010820:0.011069:0.011162:0.005184:0.009106:0.011391:0.003447:0.006209:0.011048:0.003447:0.005615:0.011687:0.009291:0.009108:0.006437:0.005547:0.009838:0.008811:0.006437:0.005615:0.011459:0.009861:0.003447:0.017280:0.011071:0.006551:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.003447:0.005615:0.011756:0.003447:0.006620:0.011299:0.009039:0.003447:0.010822:0.006617:0.011302:0.009039:0.007807:0.003447:0.009405:0.005387:0.005182:0.008948:0.005182:0.008743:0.004497:0.003447:0.008994:0.010843:0.017645:0.017485:0.010843:0.011756:0.003447:0.006026:0.010843:0.007807:0.003447:0.013354:0.012167:0.010432:0.010432:0.004109
or BRCA1 inactivation in ovarian and breast cancer:@0.147059:0.909732:0.579852:0.909732:0.579852:0.889359:0.147059:0.889359:0.010843:0.007807:0.003903:0.012463:0.013308:0.014678:0.014929:0.010432:0.003903:0.005615:0.011687:0.009291:0.009108:0.006437:0.005547:0.009838:0.008811:0.006437:0.005547:0.010843:0.011756:0.003903:0.005615:0.011756:0.003903:0.010866:0.009838:0.009085:0.007807:0.005798:0.009085:0.011756:0.003903:0.009085:0.011596:0.011391:0.003903:0.010820:0.007442:0.009288:0.009291:0.007510:0.006437:0.003903:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807
77,159:@0.579906:0.902116:0.612937:0.902116:0.612937:0.890238:0.579906:0.890238:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082
; or promoter, enhancer or other :@0.612936:0.909732:0.886426:0.909732:0.886426:0.889359:0.612936:0.889359:0.004497:0.003903:0.010843:0.007807:0.003903:0.011071:0.007442:0.010843:0.017485:0.010820:0.006209:0.009039:0.006255:0.004497:0.003903:0.009039:0.011870:0.011391:0.009085:0.011596:0.008994:0.009039:0.007807:0.003903:0.010845:0.007807:0.003903:0.010820:0.006620:0.011299:0.009039:0.007807:0.004109